Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Onsite Clinical Solutions, LLC

Neither a doctor nor a teaching hospital

Research payments

$1,994,502

314 payments

Through program year 2025, Onsite Clinical Solutions, LLC is reported as receiving $1,994,502 in research payments, across 314 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $196,997 32
2024 Research $403,120 51
2023 Research $643,335 94
2022 Research $61,862 12
2021 Research $142,976 22
2020 Research $50,473 14
2019 Research $495,739 89

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $397,872 39 payments
  2. AstraZeneca UK Limited $372,853 8 payments
  3. AbbVie, Inc. $336,546 70 payments
  4. Cordis US Corp. $256,309 11 payments
  5. Novo Nordisk AS $180,682 87 payments
  6. F. Hoffmann-La Roche AG $150,344 57 payments
  7. GW Research Limited $115,275 24 payments
  8. Amgen Inc. $105,064 2 payments
  9. E.R. Squibb & Sons, L.L.C. $69,985 3 payments
  10. Sagent Pharmaceuticals, Inc. $8,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. M16-100 $336,546 70 payments
  2. A Phase 2b Randomised,Double blind,Placebo controlled,Multi centre,Dose ranging Study of AZD3427 in Participants with Heart Failure and Pulmonary Hypertension due to Left Heart Disease WHO Group 2 $322,005 2 payments
  3. A Multicenter, Prospective, Randomized, Controlled, Open Label Trial to Evaluate the Safety and Efficacy of Mynx Control Venous Vascular Closure Device 6F-12F VS. Manual Compression in Patients Who Have Undergone Endovascular Procedures Utilizing Up to 12F Procedural Sheaths $256,309 11 payments
  4. Roll Over Protocol for 3 Ocr Pivotal Studies Opera I Opera II and Oratorio to Extend the Ole $150,344 57 payments
  5. An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) $136,368 4 payments
  6. Gwep1415 $115,275 24 payments
  7. AstraZeneca is developing mAbs to the SARS CoV 2 spike protein. The SARS CoV 2 spike protein contains the virus RBD which enables the virus to bind to receptors on human cells. By targeting this region of the virus spike protein antibodies can block the virus attachment to human cells and therefore is expected to block infection. Amino acid substitutions have been introduced into the antibodies to both extend their half lives which should prolong their potential prophylactic benefit and decrease $104,833 16 payments
  8. US Pt Satisfaction $84,162 1 payment
  9. Ex9536-4388 $76,628 15 payments
  10. A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler $63,161 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record